The cost of diabetes in Latin America and the Caribbean in 2015: Evidence for decision and policy makers.
The cost of diabetes in Latin America and the Caribbean in 2015: Evidence for decision and policy makers.
复制标题
DOI：
10.7189/jogh.07.020410
复制
发表时间：
2017-12
影响因子：
7.2
通讯作者：
Qiang A
中科院分区：
文献类型：
--
作者：
Barcelo A;Arredondo A;Gordillo-Tobar A;Segovia J;Qiang A
中等收入国家糖尿病患病率上升所带来的财政影响是卫生系统筹资和整个社会面临的主要挑战之一。本研究的目的是估计2015年拉丁美洲和加勒比地区（LAC）糖尿病的经济成本。该研究使用基于患病率的方法估计了2015年29个拉丁美洲和加勒比地区国家与糖尿病相关的直接和间接费用。直接费用包括医疗保健支出，如药物（胰岛素和口服降糖药）、检查、咨询、住院、急诊和治疗并发症。采用两种不同的情景（S1和S2）来分析直接成本。S1假设保守估计，而S2假设药物和服务的覆盖范围更广。间接费用包括因过早死亡、暂时和永久残疾而造成的资源损失。2015年，拉丁美洲和加勒比地区估计有超过4100万成年人（20岁及以上）患有糖尿病。糖尿病造成的间接总成本为571亿美元，其中275亿美元是由于过早死亡，162亿美元是由于永久性残疾，133亿美元是由于暂时性残疾。直接总费用估计在450亿至660亿美元之间，其中估计费用最高的是并发症治疗费用（1616亿至260亿美元）。其他估计表明，胰岛素的费用在60亿至110亿美元之间；口服药物40亿至60亿美元；50亿至60亿美元的磋商；住院费用100亿美元；紧急访问10亿美元；化验和实验室检查费用在100万至300万美元之间。拉丁美洲和加勒比地区2015年糖尿病的总费用估计在1020亿至1230亿美元之间。在拉丁美洲和加勒比地区，治疗一例糖尿病（DM）的年平均费用估计在1088美元至1818美元之间。拉丁美洲和加勒比地区的人均国家卫生支出平均为1061美元。2015年，糖尿病是拉丁美洲和加勒比国家的一个主要经济负担。这里提出的估计数是决策的关键信息，可用于制定政策和规划，以提高拉丁美洲和加勒比地区29个国家预防糖尿病资源的使用效率和效果。
The financial implications of the increase in the prevalence of diabetes in middle–income countries represents one of the main challenges to health system financing and to the society as a whole. The objective of this study was to estimate the economic cost of diabetes in Latin America and the Caribbean (LAC) in 2015. The study used a prevalence–based approach to estimate the direct and indirect costs related to diabetes in 29 LAC countries in 2015. Direct costs included health care expenditures such as medications (insulin and oral hypoglycemic agents), tests, consultations, hospitalizations, emergency visits and treating complications. Two different scenarios (S1 and S2) were used to analyze direct cost. S1 assumed conservative estimates while S2 assumed broader coverage of medication and services. Indirect costs included lost resources due to premature mortality, temporary and permanent disabilities. In 2015 over 41 million adults (20 years of age and more) were estimated to have Diabetes Mellitus in LAC. The total indirect cost attributed to Diabetes was US$ 57.1 billion, of which US$ 27.5 billion was due to premature mortality, US$16.2 billion to permanent disability, and US$ 13.3 billion to temporary disability. The total direct cost was estimated between US$ 45 and US$ 66 billion, of which the highest estimated cost was due to treatment of complications (US$ 1 616 to US$ 26 billion). Other estimates indicated the cost of insulin between US$ 6 and US$ 11 billion; oral medication US$ 4 to US$ 6 billion; consultations between US$ 5 and US$ 6 billion; hospitalization US$ 10 billion; emergency visits US$ 1 billion; test and laboratory exams between US$ 1 and US$ 3 million. The total cost of diabetes in 2015 in LAC was estimated to be between US$ 102 and US$ 123 billion. On average, the annual cost of treating one case of diabetes mellitus (DM) in LAC was estimated between US$ 1088 and US$ 1818. Per capita National Health Expenditures averaged US$ 1061 in LAC. Diabetes represented a major economic burden to the countries of Latin America and the Caribbean in 2015. The estimates presented here are key information for decision–making that can be used in the formulation of policies and programs to achieve greater efficiency and effectiveness in the use of resources for diabetes prevention in the 29 countries of LAC.
登录
查看更多内容
影响因子：
5.1
作者：
Fernandes, Joao da Rocha;Ogurtsova, Katherine;Makaroff, Lydia E.
通讯作者：
Makaroff, Lydia E.
影响因子：
4.6
作者：
Elgart, Jorge F.;Asteazaran, Santiago;Jose Gagliardino, Juan
通讯作者：
Jose Gagliardino, Juan
影响因子：
2.6
作者：
Commendatore, V.;Dieuzeide, G.;Gagliardino, J. J.
通讯作者：
Gagliardino, J. J.
影响因子：
9.3
作者：
Arredondo, Armando
通讯作者：
Arredondo, Armando
影响因子：
1.7
作者：
de Moura, Alda Alice Gomes;de Carvalho, Eduardo Freese;da Silva, Neiton Jose Carvalho
通讯作者：
da Silva, Neiton Jose Carvalho